| Style | Citing Format |
|---|---|
| MLA | Aliabadi M, et al.. "Co-Administration of Empagliflozin and Curcumin Attenuates the Development of Masld by Modulating Lipid Metabolism and Adipose Tissue Browning in Hfd-Fed C57bl/6J Mice." Life Sciences, vol. 405, no. , 2026, pp. -. |
| APA | Aliabadi M, Soleimani A A, Taheripak G, Nourbakhsh M, Meshkani R (2026). Co-Administration of Empagliflozin and Curcumin Attenuates the Development of Masld by Modulating Lipid Metabolism and Adipose Tissue Browning in Hfd-Fed C57bl/6J Mice. Life Sciences, 405(), -. |
| Chicago | Aliabadi M, Soleimani A A, Taheripak G, Nourbakhsh M, Meshkani R. "Co-Administration of Empagliflozin and Curcumin Attenuates the Development of Masld by Modulating Lipid Metabolism and Adipose Tissue Browning in Hfd-Fed C57bl/6J Mice." Life Sciences 405, no. (2026): -. |
| Harvard | Aliabadi M et al. (2026) 'Co-Administration of Empagliflozin and Curcumin Attenuates the Development of Masld by Modulating Lipid Metabolism and Adipose Tissue Browning in Hfd-Fed C57bl/6J Mice', Life Sciences, 405(), pp. -. |
| Vancouver | Aliabadi M, Soleimani A A, Taheripak G, Nourbakhsh M, Meshkani R. Co-Administration of Empagliflozin and Curcumin Attenuates the Development of Masld by Modulating Lipid Metabolism and Adipose Tissue Browning in Hfd-Fed C57bl/6J Mice. Life Sciences. 2026;405():-. |
| BibTex | @article{ author = {Aliabadi M and Soleimani A A and Taheripak G and Nourbakhsh M and Meshkani R}, title = {Co-Administration of Empagliflozin and Curcumin Attenuates the Development of Masld by Modulating Lipid Metabolism and Adipose Tissue Browning in Hfd-Fed C57bl/6J Mice}, journal = {Life Sciences}, volume = {405}, number = {}, pages = {-}, year = {2026} } |
| RIS | TY - JOUR AU - Aliabadi M AU - Soleimani A A AU - Taheripak G AU - Nourbakhsh M AU - Meshkani R TI - Co-Administration of Empagliflozin and Curcumin Attenuates the Development of Masld by Modulating Lipid Metabolism and Adipose Tissue Browning in Hfd-Fed C57bl/6J Mice JO - Life Sciences VL - 405 IS - SP - EP - PY - 2026 ER - |